Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy.

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...